Ben is recognised as one of Australia's leading intellectual property lawyers. He has extensive experience as an intellectual property specialist leading IP disputes and transactions in one of Australia’s pre-eminent IP teams. Ben is a patent and technology specialist with a degree in science (biochemistry) and leading expertise in IP licensing and commercialisation transactions, IP advice, litigation and dispute resolution. He also advises on pharmaceutical, biopharmaceutical and medical device regulatory matters, including on product registration and reimbursement issues, clinical trials, product launches and pharmaceutical supply and marketing issues.
Acting for Samsung Bioepis in successfully resisting an application to the Federal Court by Pfizer for preliminary discovery of documents relating to the manufacturing of Samsung Bioepis’s biosimilar etanercept product.
Acting for Sun Pharma in proceedings brought in the Federal Court by Mylan Health for alleged infringement of three patents for formulations and second medical uses of fenofibrate, together with cross claims for revocation of the patents.
St Vincent’s Hospital Sydney
Acting for St Vincent’s Hospital Sydney in negotiating patent license agreements with AVEO Pharmaceuticals, Inc. and Novo Nordisk granting exclusive worldwide rights to commercialise MIC-1, analogues and antibodies for a range of indications.
Medical device company
Acting for a leading medical device company in drafting and negotiating a number of transactions with suppliers, manufacturers and collaborators for the development of components for medical devices, including resolution of product supply, joint development, technology access and IP license and commercialisation issues.
Acting for Actavis in proceedings brought in the Federal Court by Orion Corporation and Novartis Pharmaceuticals and on appeal to the Full Court for alleged infringement of a patent for triple formulations of levodopa, carbidopa and entacapone, and a cross claim for revocation of the patent.
Maddocks appoints leading intellectual property partner
Maddocks has appointed one of Australia’s leading intellectual property lawyers.
Federal Court dismisses Pfizer’s application for preliminary discovery regarding Sandoz’s etanercept biosimilar
Implications of the Federal Court’s dismissal of Pfizer’s application for preliminary discovery from Sandoz
First detailed judicial consideration of the new support requirements for patents in Australia
We discuss the Federal Court’s decision in Merck v Wyeth, which is the first detailed judicial consideration of the new...